Filmgrid is a blockchain platform for commerce, streaming and financing of independent films and ...
Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success. Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders. Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.
Xeophin Pt y Ltd is a Melbourne, Australia based, Biotech Company with a focus on imunomodulating technologies, and is commit ted to the research, development and commercialisation of new and novel medical treatment s, in a number of high grow th therapeutic areas such as inflammation.
Our mission and vision are simple: “Take our core technologies and drive them through our six step process. The outcome being a transaction ready and IP protected technolog y por t folio. From this Xeophin will under take commercialisation activities to achieve a significant royalt y deal, delivering value to our XeR A-1 Token holders”.
In his position as Chief Executive Of ficer, Troy Neilson brings significant, relevant and recent Biotech experience along with extensive management skills. Travis Molloy as Executive Chairman brings 15 years experience in the development stage Biotech space and governance. Caroline Cook as Non-Executive Director brings to the organisation a wealth of project management, outsourcing and leadership experience.
Xeophin is currently a private and unlisted Australian company. Formal policies and best practice from Corporate Governance to Financial Management have been implemented from inception. Xeophin will reorganise and transition it self into the USA , this entit y is referred to NewCo at this stage. It is the NewCo entit y that will seek SEC compliance and undertake the formal ICO*.
Experts are independently and voluntarily contributing to the community. If no expert has rated the ICO, only ICO analyzer's results are used. Always research before investing as these ratings should not be taken as an investing guide of any kind.
Ratings and ICO analyzer results are being updated (re-calculated) every few hours.